New Delhi: Soon after reviewing the COVID-19 vaccine development at Ahmedabad’s Zydus Cadila Biotech plant, Prime Minister Narendra Modi on Saturday lauded the team for its effort and asserted that the government is actively working with them to support them in this journey.Also Read - PM Kisan Samman Nidhi Yojana: Farmers Must Complete e-KYC By THIS Date to Receive 11th Installment

Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D is over and it has commenced phase-II clinical trials from August. Also Read - Narendra Modi Hosts Deaflympics Contingent, Says 'You Brought Pride And Glory For India'

“Visited Zydus Biotech Park in Ahmedabad to know more about the indigenous DNA-based vaccine being developed by Zydus Cadila. I compliment the team behind this effort for their work. Govt of India is actively working with them to support them in this journey”, tweeted PM Modi. Also Read - Cannes 2022: PM Modi Hails India as Country of Honour, Says 'Cinema Showcases Human Emotions'

Modi flew to the Zydus Cadila plant and held discussions with the promoters and executives of the company, as part of his three-city visit to personally review coronavirus vaccine development and manufacturing process. Speaking to PTI, an official said that the Prime Minister was extensively briefed about the vaccine development work at the plant by the company officials.

“He was briefed about the vaccine production procedure. He interacted with scientists and vaccine developers”, the official informed. PM Modi spent over an hour at the plant.

Meanwhile, he has arrived in Hyderabad to visit Bharat Biotech’s facility. Covid-19 vaccine, Covaxin, being developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology is now undergoing phase-3 trials.

The vaccine is being developed and will be manufactured at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) facility in Genome Valley in Hyderabad. Modi will be interacting with scientists and senior management of the city-based vaccine maker onthe status of Covaxin, officials said.

The PM will be flying back to the national capital after a stopover in Pune, where he will visit the Serum Institute of India (SII), which has partnered with pharma giant AstraZeneca and the Oxford University for the vaccine.